Real-Life Experience of Biologic Treatment for Asthma on Chronic Rhinosinusitis: A Finnish Cohort

Author:

Lyly Annina,Genberg Emma,Kauppi PaulaORCID,Virkkula PaulaORCID,Lee Stella E.ORCID,Laidlaw Tanya M.,Toppila-Salmi Sanna,Lundberg Marie

Abstract

<b><i>Introduction:</i></b> Biologics are used in the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The purpose of this retrospective study was to evaluate the effects of biologics initiated for asthma on coexistent CRS and the influence of comorbid factors, including aspirin-exacerbated respiratory disease (AERD) and secretory otitis media (SOM). <b><i>Methods:</i></b> A review of electronic health records (2009–2020) at a Finnish tertiary center was conducted to identify CRS patients treated with biologics for their asthma. We identified the type of biologic and treatment response, by comparing nasal polyp score (NPS), sinonasal outcome test (SNOT)-22, need for oral corticosteroids (OCS) and antibiotics, frequency of visits, and endoscopic sinus surgeries (ESS) pretreatment and during treatment. <b><i>Results:</i></b> 55 patients were treated with anti-immunoglobulin E (IgE) (<i>n</i> = 18) or anti-interleukin-5/5-receptor (IL-5/5R) (<i>n</i> = 37) biologics. Treatment lasted for an average of 4.1 years. Seventy-five percent (<i>n</i> = 41) had CRSwNP and 25% (<i>n</i> = 14) had CRSsNP. Of all patients, 24% (<i>n</i> = 13) had comorbid AERD and 22% (<i>n</i> = 12) had SOM. Biologic therapy reduced the need for OCS courses (anti-IgE, <i>n</i> = 17, <i>p</i> = 0.03; anti-IL-5/5R, <i>n</i> = 35, <i>p</i> = 0.01) and for daily OCS in anti-IL-5/5R (<i>n</i> = 35, <i>p</i> = 0.001) but not in anti-IgE patients (<i>n</i> = 16, <i>p</i> = 0.07). Biologics also improved NPS by 0.5 point (<i>n</i> = 32, <i>p</i> = 0.009) and SNOT-22 by 14 points (<i>n</i> = 7, <i>p</i> = 0.02) in CRSwNP patients. The overall discontinuation rate was 37.7% (<i>n</i> = 20) and was independent of type of biologic. <b><i>Conclusion:</i></b> Treatment with anti-IgE and/or anti-IL-5/5R biologics reduced the overall need for OCS medication in individuals with asthma and concomitant CRS, but despite this, the discontinuation rate was high.

Publisher

S. Karger AG

Subject

Immunology,General Medicine,Immunology and Allergy

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3